anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Idiopathic Sudden Sensorineural Hearing Loss (ISSHL) is a sudden onset, unexplained sensorineural hearing loss. Depression is a common mental disorder and a leading cause of disability. Here, We used a two-sample Mendelian randomization approach using pooled statistics from genome-wide association studies of ISSHL (1491 cases, 196,592 controls) and depression (23,424 cases, 192,220 controls) in European populations. This study investigated the bidirectional relationship between single nucleotide polymorphisms associated with depression and ISSHL using inverse variance weighting.Additional sensitivity analyses, such as Mendelian randomization-Egger (MR-Egger), weighted median estimates, and leave-one-out analysis, were performed to assess the reliability of the findings. Significant causal association between genetic susceptibility to ISSHL and depression in a random-effects IVW approach (OR = 1.037, 95% CI = 1.004-1.072, P = 0.030). In contrast, genetic depression was not risk factors for ISSHL (OR = 1.134, 95% CI = 0.871-1.475, P = 0.350). After validation by different MR methods and the sensitivity analysis, all of the above results are consistent. The evidence we have gathered suggests a causal relationship between ISSHL and depression. The presence of the former induces or further exacerbates the latter, whereas a similar situation does not exist when the latter is an influencing factor.
Iron is an essential nutrient in living organisms with multiple vital functions. Iron deficiency (ID) can cause long term health consequences beyond iron deficiency anemia (IDA). The high prevalence of ID and its long-term effects in patients with obesity and after metabolic and bariatric surgery (MBS) is recognized. Nevertheless, there is limited knowledge of the optimal route or dose for treatment of patients with obesity and post-MBS, and an evidence-based universal guideline for prevention and treatment of ID in short- and long-term post-MBS (PMBS) is not yet available. ID in the general population is currently treated with oral or parenteral iron, where oral iron treatment is considered the preferred option with parenteral iron as a second-line treatment in case there is intolerance or lack of response to oral iron. In patients with obesity with chronic low-grade inflammation and PMBS patients with altered gut anatomy and function, there are also alterations in the bioavailability and higher risks of side effects of available oral irons. The conclusions of current studies exploring effective treatment of iron deficiency in this population have been inconsistent and further well-planned randomized and prospective studies are needed. This is a narrative review of the literature on the available treatment options and strategies for treatment of ID in PMBS patients to recognize the knowledge gaps and provides topics of future research.
Participants will receive Durvalumab for 13 cycles every 4 weeks (q4w) for a maximum 12 months. All participants will receive BCG (supplied by the site) intravesically, as induction weekly for 6 weeks. Patients will subsequently receive BCG for maintenance for 3 weekly doses at 3,6,12,18, and up to 24 months, at the physician's discretion.
The study intervention includes a telemonitoring program for high-risk pregnant women, which will be delivered using the telemonitoring platform. The trial will administer the telemonitoring program to 50 pregnant women at high risk for preeclampsia. The intervention will enable pregnant women to take daily blood pressure readings at home with a provided Bluetooth-enabled home blood pressure monitor, to report if participants have symptoms, and to receive automated alerts and self-care messages (e.g., instructing patients to repeat blood pressure readings, call a medical officer, visit the emergency department, etc.). A healthcare provider (medical officer) will receive alerts from the telemonitoring system if the patient's blood pressure trends are out of the target or if the patient is reporting symptoms.
Acute overdosage with phendimetrazine tartrate may manifest itself by the following signs and symptoms: unusual restlessness, confusion, belligerence, hallucinations, and panic states. Fatigue and depression usually follow the central stimulation. Cardiovascular effects include arrhythmias, hypertension, or hypotension and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal cramps. Poisoning may result in convulsions, coma, and death.

The management of overdosage is largely symptomatic. It includes sedation with a barbiturate. If hypertension is marked, the use of a nitrate or rapid-acting alpha receptor-blocking agent should be considered. Experience with hemodialysis or peritoneal dialysis is inadequate to permit recommendations for its use.

Dosage should be individualized to obtain an adequate response with the lowest effective dosage. 

Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F)
PURPOSE:To stably bond an antigen, an antibody and enzyme to a solid phase through chemical bond, by coating the surface of a carrier with a polymer with number average MW of 20-5,000 and constituting the terminal group of said polymer of an ethylene group. CONSTITUTION:4kg of an ethylene/vinyl acetate copolymer (EVA) pellet (m.p. 75 deg.C) having an average diameter of 1.4mm and an average length of 1.5mm obtained by a water strand method is added to 20l of a 0.5% polyvinyl alcohol (polymerization degree: about 500) aqueous solution to be mixed with and dispersed in said solution by a propeller type stirrer. Next, the resulting mixture is heated to 95 deg.C by a coil heater to be continuously stirred for 1hr and naturally cooled by stopping heating. After cooling, the resin separated, washed and dried. The resin thus obtained has a spherical shape with a diameter of 1.65% mm having a smooth surface and is obtained at 95% yield.
Participants in the control group will complete the baseline study activities, as described above. If symptoms arise or COVID-19 infection occurs, participants will test and seek care as they normally would.
FIELD: medicine, immunopharmacology, pharmacy, biochemistry. SUBSTANCE: method involves determination of the NADPH-oxidase reaction rate in white cell homogenates or in fraction of polymorphonuclear leukocytes of peripheral blood before and after addition of substances to be study to sample. Immunomodulating activity is detected by increase of the NADPH-oxidase reaction rate. Specific property of immunomodulating agents is a direct activation of NADPH-oxidase in homogenates of nonactivated white cells of peripheral blood and peritoneal macrophages. The property of potential immunomodulating agents to activate NADPH-oxidase in homogenates of "resting" white cells of peripheral blood and macrophages by their direct addition to homogenates in vitro is proved on example of immunomodulating agents of different structure, for example, as pyrimidine derivative (uracil), polypetide preparation Tactivin from cattle thymus gland, coneflower herb dry extract where sesquiterpene lactones are the acting component. Specificity of claimed method is proved on the basis of absence of activating effect of dragonhead herb dry extract showing antioxidant properties. Invention ensures to enhance sensitivity and economy of detection of immunomodulating activity in vitro. EFFECT: improved method of detection. 4 ex
A No 3 polyester suture will be inserted into the external urethral ligament, into the uurethral part of pubourethral ligament and into the pubic part of the pubourethral lgament then will be tied, but not tightly. The interventions will be carried on either side of the urethra that will be opened up by an 2.5 cm incision in the periurethral sulci.
PURPOSE:To obtain a composition for the oral cavity useful for suppressing a formation of bacterial plaques and preventing gingivitis by allowing to contain a cationic germicidal agent and polyvinyl pyrrolidone and no detergents except the cationic germicidal agent. CONSTITUTION:This composition for the oral cavity is allowed to contain 0.0001-50wt.% cationic germicidal agent (e.g. benzethonium chloride) and 0.001-20wt.% polyvinyl pyrrolidone having 10000-360000 average molecular weight as a stabilizer thereof. This composition is prepared to formulate a mouth refrigerant such as a tooth paste, a liquefied tooth wash, a tooth wash, a moistened tooth cleaner, a mouth wash, a mouth spray, etc., a teeth coating agent, a dental prosthesis coating agent, a dental prosthesis cleaning agent, etc., by usual methods. Here, a surfactant except cationic germicides is not included. This composition makes the most of the germicidal activity of the cationic germicide and is excellent in stability with the passage of time.
The invention belongs to the field of foods and relates to a use of licorice root in a composite health beverage with effects of clearing heat from throat and benefiting throat. The composite health beverage is prepared from licorice root, cassia seeds, longan pulp, wolfberry fruits, rhizoma polygonati, mulberry, chrysanthemum, raspberry, mint, semen astragali complanati, semen cuscutae, red dates, radix curcumae and fructus trichosanthis. The composite health beverage has effects of dispelling wind and heat with drugs pungent in flavor and cool in property, moistening lung, reducing phlegm and relieving wind-heat sore-throat. Through advantages of the medicinal materials, the composite health beverage has the characteristics of good health effects and good taste. Compared with other dosage forms, the composite health beverage can be used timely and conveniently and can be accepted by more and more pharyngitis patients. The composite health beverage can be prepared through scientific and feasible processes, has strong operability, greatly reduces a production cost and provides considerable economic benefits for production enterprises.
Constitutional chromosomal abnormalities play a significant role in causing reproductive anomalies in individuals of reproductive age. With the rapid advancement of genome engineering techniques, it has now become possible to cure different genetic disorders. However, very limited data is available regarding the prevalence of such aberrations in the Pakistani population. Considering this factor, this retrospective analysis was undertaken to elucidate the type and prevalence rate of such abnormalities in our population. A total of 241 individuals, who were referred to the Liaquat National Hospital, from January 2017 to December 2021, with a history of infertility or miscarriages, were evaluated using the standard GTG banding technique. The results revealed a notably high percentage 44(18.2%) of chromosomal abnormalities in our population. Surprisingly, the frequency of these anomalies was observed to be higher in males than in females. However, further research is needed using a larger sample size to confirm the findings of this investigation.
Female college students who use unhealthy weight control methods and have body image concerns may be at risk for developing an eating disorder. Developing and evaluating interventions to reduce eating disorders in high-risk populations is of great public health importance.

Participants are randomly assigned to either join a web-based risk-reduction program or receive no intervention. The 9-week risk-reduction program focuses on reducing body image and weight/shape concerns, identifying the risks of eating disorders, and increasing healthy weight regulation practices. The program includes weekly readings, writing assignments, and participation in a moderated electronic discussion group. Changes in body mass index (BMI) and the occurrence of major stressors and psychiatric events are assessed to determine their impact on the incidence of eating disorders. One-year incidence of eating disorders is determined by a diagnostic interview, and follow up may continue for up to 2.5 years.
Participants will be given standard of care for constipation (handout) to utilize during the 8-week intervention period. A study dietitian will follow up with weekly phone calls to support adherence and monitor for adverse events.
The control group will not be included in any exercise program, and they will be informed that they can participate in the same program after 16 weeks if they prefer. At the same time, a one-session training will be given to all participants of intervention and control groups at the Kadıköy Municipality Social Life Center, where information about the factors that increase the risk of falling and house arrangements will be provided.
According to this Tisserand Institute guide chart, for a 2% dilution process, dilution will be provided with a total of 12 drops by adding 4:4:4 drops of lavender, Roman chamomile and ginger essential oils in 20 ml of sweet almond oil. Expert opinion was obtained from a phytotherapy and aromatherapy specialist physician that the oils and dilution rates used were appropriate. Foot massage will be applied on the 1st, 2nd and 3rd postoperative days. State Anxiety Scale, Visual Analogue Scale (VAS-F), Visual Analogue Scale (VAS-P), Post-operative Nausea-Vomiting Impact Scale will be applied before and after the application.Richard-Campbell Sleep Quality Scale will be applied before application Foot massage will be applied for 20 minutes.
Patients undergo radiation therapy to the prostate bed over 2 - 6 weeks. Additionally, patients undergo PET, CT or MRI and blood sample collection throughout the study.
There is provided a gel composition having a silica powder and a non-volatile compound. The silica powder particles are spherical and porous. The silica powder has a specific gravity about 0.09 to about 0.6, and is present in an amount about 10 wt % to about 50 wt %. The non-volatile compound is present from about 35 wt % to about 90 wt %. The composition has less than about 5 wt % water. There is also provided a method for imparting a powdery feel to the skin, and a method for treating a cosmetic or medical condition of the skin, nail/cuticle, lips or hair.
PURPOSE: The effect of overactive bladder (OAB) on sexual health has been evaluated extensively for women but much less for men. Therefore, the aim of this study was to evaluate the relationship between OAB and men's sexual activity and the effect of OAB on erectile dysfunction (ED) and premature ejaculation (PE) in a large representative cohort of men at the population level.
METHODS: This study was based on computer-assisted web interviews that used validated questionnaires. The most recent census and the sample size estimation calculations were employed to produce a population-representative pool.
RESULTS: The study included 3001 men, representative of the population in terms of age and place of residence. The frequency of sexual intercourse was higher for respondents without OAB symptoms compared with persons who had OAB (p = 0.001), but there was no association between OAB symptoms and number of sexual partners (p = 0.754). Regression models did not confirm the effect of OAB on sexual activity (odds ratio 0.993, CI 0.974-1.013, p = 0.511). Both ED and PE were more prevalent in respondents with OAB symptoms compared with persons who lacked those symptoms (p < 0.001). Importantly, the effect of OAB on ED or PE was independent of age, comorbidities, and lifestyle habits (regression coefficients of 0.13 and 0.158 for ED and PE, respectively).
CONCLUSION: Overactive bladder did not significantly affect men's sexual activity, but it significantly correlated with ED and PE. Our results suggest a need in daily clinical practice to screen for OAB symptoms for persons who report ED or PE.
The present invention provides compositions and methods for extending the release times and lowering the toxicity of pharmacologically active compounds.  The compounds comprise a salt of the pharmacologically active compound with a lipophilic counterion and a pharmaceutically acceptable water immiscible solvent. In one embodiment the compositions are provided as injectable compositions. The lipophilic counterion may be a saturated or unsaturated C8-C22 fatty acid, and preferably may be a saturated or unsaturated C10-C18 fatty acid. The compositions are released over time when administered to a mammal.  Therefore, the present invention enables one to provide a controlled dose administration of the active compound for periods of up to 15 days or even longer. Many compounds can be administered according to the present invention, including, but not limited to, tilmicosin, oxytetracycline, fluoxetine, roxithromycin, and turbinafine.
The present invention relates to a composition for theragnosis for skin sclerosis containing bifidobacterium sp. as an active ingredient. Bifidobacterium sp. strains of the present invention control an immune function by reducing Th1 cells, Th2 cells, and Th17 cells. When the bifidobacterium sp. strains are applied to a patient with the skin sclerosis with the reduced total number of strains of bifidobacterium when analyzing the total number of intestinal strains, increase of the total number of intestinal strains is induced. Therefore, the bifidobacterium sp. strains of the present invention reduce thickness of skin, and provide excellent effects of preventing and treating the skin sclerosis by suppressing skin fibrosis. In addition, after treating a conventional treatment drug for the skin sclerosis, the present invention effectively confirms increasing/reducing degrees of intestinal bifidobacterium, and is used as an index of determining and diagnosing a treatment degree of the treatment drug based on the same. Accordingly, the bifidobacterium sp. strains of the present invention are applied to a theragnosis technology which can be applied to a new concept diagnosis/treatment technology for early diagnosing and treating an immune disorder such as the skin sclerosis at the same time.
120 patients with malignant tumors diagnosed by pathology or cytology and treated with highly emetogenic chemotherapy drugs containing cisplatin from September 2018 to December 2019 were selected. The patients were randomly assigned to megestrol group (megestrol acetate dispersible tablets+5-HT3 receptor antagonist+dexamethasone) or control group (5-HT3 receptor antagonist + dexamethasone) at 1:1. The dosage of antiemetic drugs in the control group: 5-HT3 receptor antagonist 2.5mg, dexamethasone 12mg on the first day, 8mg on the 2nd-4th day, all were injected intravenously with 30min before chemotherapy for 5 days. The patients in the megestrol acetate group were given megestrol acetate dispersible tablets on the basis of the control group. 160 mg of megestrol acetate dispersible tablets were taken orally every morning on the day of the beginning of chemotherapy for 10 days. The main end point was the proportion of control of nausea and vomiting between the two groups during the delayed period (24-120 hours after the beginning of chemotherapy), that is, the proportion of complete remission (no vomiting and no need for rescue treatment) and complete prevention (no nausea and vomiting).The secondary end point was the control ratio of nausea and vomiting in the acute phase (0-24 hours after the beginning of chemotherapy) and the overall phase (0-120 hours after the beginning of chemotherapy); the proportion of patients with grade 3-4 nausea and vomiting during chemotherapy; the adverse reactions related to antiemetic drugs and the score of quality of life of patients in both groups before and after treatment.
Erectile dysfunction (ED) incidence is higher in patients with obstructive sleep apnea (OSA). Studies have suggested that ED and OSA may activate similar pathways; however, few have investigated the links between their underlying genotypic profiles. Therefore, we conducted an in-silico analysis to test whether ED and OSA share genetic variants of risk and to identify any molecular, cellular and biological interactions between them. Two gene lists were manually curated through a literature review based on a PUBMED search, which resulted in one gene list associated with ED (total of 205 genes) and the other with OSA (total of 2622 genes). Between those gene sets, 35 were common for both lists (Fisher exact test, p-value = 0.027). The Protein-protein interaction (PPI) analysis using the intersect list as input showed that 3 of them had direct interactions (LPL, DGKB and PLCB1). In addition, the biological function of the genes contained in the intersect list suggested that pathways related to lipid metabolism and the neuromuscular junction were commonly found in the genetic basis of ED and OSA. From the shared genes between both conditions, the biological pathways highlighted in this study may serve as preliminary findings for future functional investigations on OSA and ED association.
The invention discloses a meat type beast and bird bone ultrafine powder and manufacturing method. It uses bone powder as material, uses food additives as assistant material. The weight percentage proportion of components is: food fillers: 0.02-20%; oxidation inhibitor: 0.0001-0.05%; the residue is ultramicro powder of beast and bird. The process is: the fresh bone is crashed, in temperature of 50deg.C-65deg.C and pH value 6.5-7.0, it is decomposed for 2-4 hours with enzyme; centrifugal deoilling, the fat content of the material is not more than 10%; then adds in the additives, carries on thermal retardation for 0.5-1 hours in temperature of 80-95deg.C; then carries on pulverization and drying. The temperature is low; the nutriment in bones can be reserved totally. It uses enzyme biology technology, the protein in the bone is changed into small molecular peptide and amino acid, thus the product is rich in calcium, phosphorus, amino acid and small molecular peptide.
BACKGROUND: Anatomic patellar components for total knee arthroplasty (TKA) have demonstrated favorable in vivo kinematics. A novel failure mechanism in TKA patients with an anatomic patellar component was observed prompting an investigation to identify patient- and implant-related factors associated with suboptimal performance.
METHODS: A retrospective evaluation was performed comparing 100 TKA patients with an anatomic patellar component to 100 gender-, age-, and body mass index-matched patients with a medialized dome component. All surgeries were performed with the same posterior-stabilized TKA system with minimum of 1-year follow-up. Several radiographic parameters were assessed. A separate computational evaluation was performed using finite-element analysis, comparing bone strain energy density through the patella bone remnant.
RESULTS: Patients with an anatomic patellar component had significantly higher rates of anterior knee pain (18 versus 2%, P < .001), chronic effusions (18 versus 2%, P < .001), and superior patellar pole fragmentation (36 versus 13%, P < .001) compared to those with a dome component. Radiographically, the anatomic group demonstrated more lateral patellar subluxation (2.3 versus 1.1 mm, P < .001) and lateral tilt (5.4 versus 4.0 mm, P = .013). Furthermore, there were more revisions in the anatomic group (7 versus 3, P = .331). On computational evaluation, all simulations demonstrated increased bone strain energy density at the superior patellar pole with the anatomic patella. Resection thickness <13 mm resulted in over 2-fold higher strain energy density, and negative resection angle of 7° resulted in 6-fold higher superior pole strain energy.
CONCLUSIONS: Patients with an anatomic patellar component showed higher rates of anterior knee pain, chronic effusion, and superior pole fragmentation compared to patients with a dome patella, with higher superior patellar pole strain energy confirmed on computational evaluation. Avoiding higher resection angles and excessive patellar resection may improve the performance and survivorship of the anatomic patella.